Loading…
Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy
Study Type – Prognosis (individual cohort) Level of Evidence 2b What’s known on the subject? and What does the study add? Cardiovascular disease is a leading cause of death in prostate cancer patients. Pretreatment ED is a surrogate for vascular pathology. Aggressive treatment of medical co‐morbidit...
Saved in:
| Published in: | BJU international 2012-01, Vol.109 (2), p.220-225 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563 |
| container_end_page | 225 |
| container_issue | 2 |
| container_start_page | 220 |
| container_title | BJU international |
| container_volume | 109 |
| creator | Bittner, Nathan Merrick, Gregory S. Galbreath, Robert W. Butler, Wayne M. Lief, Jonathan H. Allen, Zachariah A. Wallner, Kent E. |
| description | Study Type – Prognosis (individual cohort)
Level of Evidence 2b
What’s known on the subject? and What does the study add?
Cardiovascular disease is a leading cause of death in prostate cancer patients. Pretreatment ED is a surrogate for vascular pathology. Aggressive treatment of medical co‐morbidity in prostate cancer patients may positively impact overall survival.
OBJECTIVE
•
To evaluate the relationship between pre‐treatment erectile function and all‐cause mortality in patients with prostate cancer treated with brachytherapy.
PATIENTS AND METHODS
•
In all, 1279 consecutive patients with clinically localized prostate cancer and pre‐implant erectile function assessed by the International Index of Erectile Function‐6 (IIEF‐6) underwent brachytherapy.
•
Potency was defined as an IIEF‐6 score of ≥13 without pharmacological or mechanical support.
•
Patients were stratified into IIEF‐6‐score cohorts (≤12, 13–23 and 24–30).
•
The median follow‐up was 5.0 years.
RESULTS
•
The 8‐year overall survival (OS) of the study population was 85.1%.
•
The 8‐year OS for IIEF‐6scores ≤12, 13–23 and 24–30 were 78.0%, 92.8% and 91.4%, respectively (P |
| doi_str_mv | 10.1111/j.1464-410X.2011.10280.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_913719077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>913719077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563</originalsourceid><addsrcrecordid>eNqNkc2KFDEQx4Mo7jr6ChIQ8TRt0kk6nYugy_rFghcXvIV0uprJ0B9jkt7dvvkE4jP6JNbszK7gyVyqKvX7J0X9CaGcFRzP623BZSXXkrNvRck4Lzgra1bcPCCn942Hdzkz1Ql5ktKWMbyo1GNyUnItBNPylPw8j-Bz6IG2S-rmEfNppCHRXYQ2YHUFdOqo6_vfP355NyegwxSz60NeaBjpzuUAY070OuQNiqaUXQbq3egh0hwBq_bYhDi4EWHUZYgphxxcT5vo_GbJG4hutzwljzrXJ3h2jCty-f7869nH9cWXD5_O3l6svSw1W3feaCXr1nFQXle-1MI3poFaat0xUFXJHSiQ3lSNbHTNWeeFUSB8xbRXlViRV4d3ceLvM6Rsh5A89D0OOM3JGi40N0xrJF_8Q26nOY44nOVCCaGYwbAi9YHyuIEUobO7GAYXF8uZ3Vtmt3bvht07Y_eW2VvL7A1Knx8_mJsB2nvhnUcIvDwCLnnXdxF3G9JfTgnDZMmRe3PgrtHO5b8HsO8-X96m4g_39LZf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353350935</pqid></control><display><type>article</type><title>Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Bittner, Nathan ; Merrick, Gregory S. ; Galbreath, Robert W. ; Butler, Wayne M. ; Lief, Jonathan H. ; Allen, Zachariah A. ; Wallner, Kent E.</creator><creatorcontrib>Bittner, Nathan ; Merrick, Gregory S. ; Galbreath, Robert W. ; Butler, Wayne M. ; Lief, Jonathan H. ; Allen, Zachariah A. ; Wallner, Kent E.</creatorcontrib><description>Study Type – Prognosis (individual cohort)
Level of Evidence 2b
What’s known on the subject? and What does the study add?
Cardiovascular disease is a leading cause of death in prostate cancer patients. Pretreatment ED is a surrogate for vascular pathology. Aggressive treatment of medical co‐morbidity in prostate cancer patients may positively impact overall survival.
OBJECTIVE
•
To evaluate the relationship between pre‐treatment erectile function and all‐cause mortality in patients with prostate cancer treated with brachytherapy.
PATIENTS AND METHODS
•
In all, 1279 consecutive patients with clinically localized prostate cancer and pre‐implant erectile function assessed by the International Index of Erectile Function‐6 (IIEF‐6) underwent brachytherapy.
•
Potency was defined as an IIEF‐6 score of ≥13 without pharmacological or mechanical support.
•
Patients were stratified into IIEF‐6‐score cohorts (≤12, 13–23 and 24–30).
•
The median follow‐up was 5.0 years.
RESULTS
•
The 8‐year overall survival (OS) of the study population was 85.1%.
•
The 8‐year OS for IIEF‐6scores ≤12, 13–23 and 24–30 were 78.0%, 92.8% and 91.4%, respectively (P < 0.001).
•
Cardiovascular events accounted for a significant portion of deaths in each IIEF‐6 group.
•
When combined with other risk factors for cardiovascular disease, an IIEF‐6 score of ≤12 had an additive effect on all‐cause mortality (IIEF‐6 score of ≤12 and less than two comorbidities vs two or more comorbidities were 18.2% and 32.1%).
CONCLUSIONS
•
A pre‐implant IIEF‐6score of ≤12 was associated with a higher incidence of all‐cause mortality.
•
Pre‐treatment erectile dysfunction is a surrogate for underlying vascular pathology, probably explaining the lower OS in this subset of patients.
•
Aggressive treatment of medical co‐morbidity is warranted to impactOS.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2011.10280.x</identifier><identifier>PMID: 21733074</identifier><identifier>CODEN: BJINFO</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Biological and medical sciences ; Biomarkers ; Brachytherapy ; Cardiovascular disease ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - mortality ; Clinical trials ; Drug therapy ; erectile dysfunction ; Erectile Dysfunction - complications ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Mortality ; Nephrology. Urinary tract diseases ; Non tumoral diseases ; Prostate cancer ; Prostatic Neoplasms - complications ; Prostatic Neoplasms - radiotherapy ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Survival Analysis ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2012-01, Vol.109 (2), p.220-225</ispartof><rights>2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL</rights><rights>2015 INIST-CNRS</rights><rights>2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563</citedby><cites>FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25390421$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21733074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bittner, Nathan</creatorcontrib><creatorcontrib>Merrick, Gregory S.</creatorcontrib><creatorcontrib>Galbreath, Robert W.</creatorcontrib><creatorcontrib>Butler, Wayne M.</creatorcontrib><creatorcontrib>Lief, Jonathan H.</creatorcontrib><creatorcontrib>Allen, Zachariah A.</creatorcontrib><creatorcontrib>Wallner, Kent E.</creatorcontrib><title>Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Study Type – Prognosis (individual cohort)
Level of Evidence 2b
What’s known on the subject? and What does the study add?
Cardiovascular disease is a leading cause of death in prostate cancer patients. Pretreatment ED is a surrogate for vascular pathology. Aggressive treatment of medical co‐morbidity in prostate cancer patients may positively impact overall survival.
OBJECTIVE
•
To evaluate the relationship between pre‐treatment erectile function and all‐cause mortality in patients with prostate cancer treated with brachytherapy.
PATIENTS AND METHODS
•
In all, 1279 consecutive patients with clinically localized prostate cancer and pre‐implant erectile function assessed by the International Index of Erectile Function‐6 (IIEF‐6) underwent brachytherapy.
•
Potency was defined as an IIEF‐6 score of ≥13 without pharmacological or mechanical support.
•
Patients were stratified into IIEF‐6‐score cohorts (≤12, 13–23 and 24–30).
•
The median follow‐up was 5.0 years.
RESULTS
•
The 8‐year overall survival (OS) of the study population was 85.1%.
•
The 8‐year OS for IIEF‐6scores ≤12, 13–23 and 24–30 were 78.0%, 92.8% and 91.4%, respectively (P < 0.001).
•
Cardiovascular events accounted for a significant portion of deaths in each IIEF‐6 group.
•
When combined with other risk factors for cardiovascular disease, an IIEF‐6 score of ≤12 had an additive effect on all‐cause mortality (IIEF‐6 score of ≤12 and less than two comorbidities vs two or more comorbidities were 18.2% and 32.1%).
CONCLUSIONS
•
A pre‐implant IIEF‐6score of ≤12 was associated with a higher incidence of all‐cause mortality.
•
Pre‐treatment erectile dysfunction is a surrogate for underlying vascular pathology, probably explaining the lower OS in this subset of patients.
•
Aggressive treatment of medical co‐morbidity is warranted to impactOS.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Brachytherapy</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>erectile dysfunction</subject><subject>Erectile Dysfunction - complications</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Non tumoral diseases</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - complications</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkc2KFDEQx4Mo7jr6ChIQ8TRt0kk6nYugy_rFghcXvIV0uprJ0B9jkt7dvvkE4jP6JNbszK7gyVyqKvX7J0X9CaGcFRzP623BZSXXkrNvRck4Lzgra1bcPCCn942Hdzkz1Ql5ktKWMbyo1GNyUnItBNPylPw8j-Bz6IG2S-rmEfNppCHRXYQ2YHUFdOqo6_vfP355NyegwxSz60NeaBjpzuUAY070OuQNiqaUXQbq3egh0hwBq_bYhDi4EWHUZYgphxxcT5vo_GbJG4hutzwljzrXJ3h2jCty-f7869nH9cWXD5_O3l6svSw1W3feaCXr1nFQXle-1MI3poFaat0xUFXJHSiQ3lSNbHTNWeeFUSB8xbRXlViRV4d3ceLvM6Rsh5A89D0OOM3JGi40N0xrJF_8Q26nOY44nOVCCaGYwbAi9YHyuIEUobO7GAYXF8uZ3Vtmt3bvht07Y_eW2VvL7A1Knx8_mJsB2nvhnUcIvDwCLnnXdxF3G9JfTgnDZMmRe3PgrtHO5b8HsO8-X96m4g_39LZf</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Bittner, Nathan</creator><creator>Merrick, Gregory S.</creator><creator>Galbreath, Robert W.</creator><creator>Butler, Wayne M.</creator><creator>Lief, Jonathan H.</creator><creator>Allen, Zachariah A.</creator><creator>Wallner, Kent E.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201201</creationdate><title>Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy</title><author>Bittner, Nathan ; Merrick, Gregory S. ; Galbreath, Robert W. ; Butler, Wayne M. ; Lief, Jonathan H. ; Allen, Zachariah A. ; Wallner, Kent E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Brachytherapy</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>erectile dysfunction</topic><topic>Erectile Dysfunction - complications</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Non tumoral diseases</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - complications</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bittner, Nathan</creatorcontrib><creatorcontrib>Merrick, Gregory S.</creatorcontrib><creatorcontrib>Galbreath, Robert W.</creatorcontrib><creatorcontrib>Butler, Wayne M.</creatorcontrib><creatorcontrib>Lief, Jonathan H.</creatorcontrib><creatorcontrib>Allen, Zachariah A.</creatorcontrib><creatorcontrib>Wallner, Kent E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bittner, Nathan</au><au>Merrick, Gregory S.</au><au>Galbreath, Robert W.</au><au>Butler, Wayne M.</au><au>Lief, Jonathan H.</au><au>Allen, Zachariah A.</au><au>Wallner, Kent E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2012-01</date><risdate>2012</risdate><volume>109</volume><issue>2</issue><spage>220</spage><epage>225</epage><pages>220-225</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><coden>BJINFO</coden><abstract>Study Type – Prognosis (individual cohort)
Level of Evidence 2b
What’s known on the subject? and What does the study add?
Cardiovascular disease is a leading cause of death in prostate cancer patients. Pretreatment ED is a surrogate for vascular pathology. Aggressive treatment of medical co‐morbidity in prostate cancer patients may positively impact overall survival.
OBJECTIVE
•
To evaluate the relationship between pre‐treatment erectile function and all‐cause mortality in patients with prostate cancer treated with brachytherapy.
PATIENTS AND METHODS
•
In all, 1279 consecutive patients with clinically localized prostate cancer and pre‐implant erectile function assessed by the International Index of Erectile Function‐6 (IIEF‐6) underwent brachytherapy.
•
Potency was defined as an IIEF‐6 score of ≥13 without pharmacological or mechanical support.
•
Patients were stratified into IIEF‐6‐score cohorts (≤12, 13–23 and 24–30).
•
The median follow‐up was 5.0 years.
RESULTS
•
The 8‐year overall survival (OS) of the study population was 85.1%.
•
The 8‐year OS for IIEF‐6scores ≤12, 13–23 and 24–30 were 78.0%, 92.8% and 91.4%, respectively (P < 0.001).
•
Cardiovascular events accounted for a significant portion of deaths in each IIEF‐6 group.
•
When combined with other risk factors for cardiovascular disease, an IIEF‐6 score of ≤12 had an additive effect on all‐cause mortality (IIEF‐6 score of ≤12 and less than two comorbidities vs two or more comorbidities were 18.2% and 32.1%).
CONCLUSIONS
•
A pre‐implant IIEF‐6score of ≤12 was associated with a higher incidence of all‐cause mortality.
•
Pre‐treatment erectile dysfunction is a surrogate for underlying vascular pathology, probably explaining the lower OS in this subset of patients.
•
Aggressive treatment of medical co‐morbidity is warranted to impactOS.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21733074</pmid><doi>10.1111/j.1464-410X.2011.10280.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2012-01, Vol.109 (2), p.220-225 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_913719077 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Aged Biological and medical sciences Biomarkers Brachytherapy Cardiovascular disease Cardiovascular Diseases - complications Cardiovascular Diseases - mortality Clinical trials Drug therapy erectile dysfunction Erectile Dysfunction - complications Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Mortality Nephrology. Urinary tract diseases Non tumoral diseases Prostate cancer Prostatic Neoplasms - complications Prostatic Neoplasms - radiotherapy Retrospective Studies Risk Factors Severity of Illness Index Survival Analysis Tumors of the urinary system Urinary tract. Prostate gland |
| title | Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A45%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erectile%20dysfunction%20is%20predictive%20of%20all%E2%80%90cause%20mortality%20in%20patients%20with%20prostate%20cancer%20treated%20with%20permanent%20interstitial%20brachytherapy&rft.jtitle=BJU%20international&rft.au=Bittner,%20Nathan&rft.date=2012-01&rft.volume=109&rft.issue=2&rft.spage=220&rft.epage=225&rft.pages=220-225&rft.issn=1464-4096&rft.eissn=1464-410X&rft.coden=BJINFO&rft_id=info:doi/10.1111/j.1464-410X.2011.10280.x&rft_dat=%3Cproquest_cross%3E913719077%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4270-fc97548da1e5c76c273cb9be8477f0e5621ae5e4c96b4b7810fc395e3c607c563%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1353350935&rft_id=info:pmid/21733074&rfr_iscdi=true |